Challenges in clinical studies with multiple imaging probes

Nuclear Medicine and Biology

Volumn 34, Issue 7, 2007, Pages 879-885

  Krohn, Kenneth A ^a   O'Sullivan, Finbarr ^a   Crowley, John ^a   Eary, Janet F ^a   Linden, Hannah M ^a   Link, Jeanne M ^a   Mankoff, David A ^a   Muzi, Mark ^a   Rajendran, Joseph G ^a   Spence, Alexander M ^a   Swanson, Kristin R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarkers; Molecular biology; Multiple imaging

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE;

ANGIOGENESIS; DIAGNOSTIC ACCURACY; MATHEMATICAL MODEL; MOLECULAR BIOLOGY; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MOLECULAR PROBE TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34848858002     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.07.014     Document Type: Review

References (30)

1. Jarvik J.G. Fundamentals of clinical research for radiologists. The research framework. AJR Am J Roentgenol 176 (2001) 873-878
2. Hartwell L., Mankoff D., Paulovich A., Ramsey S., and Swisher E. Cancer biomarkers: a systems approach. Nat Biotechnol 24 (2006) 905-908
3. Kelloff G.J., Krohn K.A., Larson S.M., Weissleder R., Mankoff D.A., et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11 (2005) 7967-7985
4. Dancey J.E. Recent advances of molecular targeted agents. Cancer Biol Ther 6 (2003) 601-609
5. Therasse P., Eisenhauer E.A., and Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42 (2006) 1031-1039
6. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39 (2003) 2012-2020
7. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 15 (2006) 553-561
8. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
9. Mankoff D.A., and Krohn K.A. PET imaging of response and resistance to cancer therapy. Chapter 5. In: Teicher B. (Ed). Cancer discovery and development: cancer drug resistance (2006), Humana Press Inc., Totowa (NJ) 105-122
10. Schumacher M., Hollander N., Schwarzer G., and Sauerbrei W. Prognostic factor studies. In: Crowley J. (Ed). Handbook of statistics in clinical oncology (2001), Marcel Dekker Inc., New York 321-378
11. Hilden J., and Habbema D.F. Prognosis in medicine: an analysis of its meaning and roles. Theor Med 8 (1987) 349-365
12. Simon R., and Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69 (1994) 979-985
13. Windeler J. Prognosis - what does the clinician associate with this notion?. Stat Med 19 (2000) 425-430
14. O'Sullivan F., Muzi M., Graham M.M., and Spence A.M. Parametric imaging by mixture analysis in 3-D validation of dual-tracer glucose studies. In: Myers R., Cunningham V.J., Bailey D.L., and Jones T. (Eds). Quantification of brain function with PET (1996), Academic Press, San Diego 297-300
15. Berman D.S., Hachamovitch R., Shaw L.J., Friedman J.D., Hayes S.W., Thompson L.E.J., et al. Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance assessment in patients with suspected coronary artery disease. J Nucl Med 47 (2006) 74-82
16. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45 (2004) 1829-1837
17. 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46 (2005) 658-666
18. 18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91 (2006) 498-505
19. Rajendran J.G., Schwartz D.L., O'Sullivan J., Paterson L.M., Ng P., Scharnhorst J., et al. Tumor hypoxia imaging with [F-18]fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12 (2006) 5435-5441
20. Green S., Benedetti J., and Crowley J. Clinical trials in oncology (2000), Chapman & Hall/CRC, Boca Raton
21. Linden H.M., Stekhova S.A., Link J.M., Gralow J.R., Livingston R.B., Ellis G.K., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 (2006) 2793-2799
22. Ludwig J.A., and Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5 (2005) 845-856
23. Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93 (2001) 1054-1061
24. Harpold H.L.P., Alvord E.C., and Swanson K.R. The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 66 (2007) 1-9
25. Loeve F., Brown M.L., Boer R., van Ballegooijen M., van Oortmarssen G.J., and Habbema D.F. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 92 (2000) 557-563
26. Vijan S., Hwang E.W., Hofer T.P., and Hayward R.A. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 111 (2001) 593-601
27. See the special issue of Science, October 2004, dedicated to "personalized medicine". Science 2004;306:640.
28. Zerhouni E.A. Translational and clinical science - time for a new vision. N Engl J Med 353 (2005) 1621-1623
29. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4 (2004) 309-314
30. Rothenberg M.L., Carbone D.P., and Johnson D.H. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 3 (2003) 303-309